A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Simes, John ^a   Voysey, Merryn ^a   O'Connell, Rachel ^a   Glasziou, Paul ^b   Best, James D ^c   Scott, Russell ^d   Pardy, Christopher ^a   Byth, Karen ^a   Sullivan, David R ^e   Ehnholm, Christian ^f   Keech, Anthony ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f BIOMEDICUM HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS; HUMANS; PLACEBOS; PROCETOFEN; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77649145926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008580     Document Type: Article

References (38)

1. White IR (2005) Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 14: 327.
2. Rosenblum M, Jewell NP, van der Laan M, Shiboski S, Van der Straten A, et al. (2009) Analysing direct effects in randomized trials with secondary interventions: an application to human immunodeficiency virus prevention trials. J R Stat Soc A172: 443-465.
3. Yamaguchi T, Ohashi Y (2004) Adjusting for differential proportions of secondline treatment in cancer clinical trials. Part I: Structural nested models and marginal structural models to test and estimate treatment arm effects. Stat Med 23: 1991-2003.
4. Heritier SR, Gebski VJ, Keech AC (2003) Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 179: 438-440.
5. Sheiner LB, Rubin DB (1995) Intention-to-treat analysis and the goal of clinical trials. Clin Pharmacol Ther 56: 6-10.
6. FIELD Study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus (the FIELD study): a randomised controlled trial. Lancet 366: 1849-1861.
7. FIELD study investigators (2004) The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ISRCTN64783481. Cardiovasc Diabetol 3: 9.
8. Nagelkerke N, Fidler V, Bernsen R, Borgdor M (2000) Estimating treatment effect in randomized clinical trials in the presence of non-compliance. Stat Med 19: 1849-1864.
9. Little RJ, Long Q, Lin X (2009) A comparison of methods for estimating the causal effect of a treatment in randomized clinical trials subject to noncompliance. Biometrics 65: 640-649.
10. Bond SJ, White IR, Walker AS (2007) Instrumental variables and interactions in the causal analysis of a complex clinical trial. Stat Med 26: 1473-1496.
11. Marcus SM, Gibbons RD (2001) Estimating the efficacy of receiving treatment in randomized clinical trials with noncompliance. Health Serv Outcomes Res Methodol 2: 247-258.
12. FIELD Study Investigators (2005) Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebocontrolled trial: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol 4: 13.
13. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
14. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419-1427.
15. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, et al. (1990) Blood pressure, stroke and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827-838.
16. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: overview of randomized trials. Prog Cardiovascular Dis 27: 335-371.
17. Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260: 2088-2093.
18. Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 355: 1955-1964.
19. Law MR, Wald NJ, Morris JK, Jordan R (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427-1431.
20. Collins R, MacMahon S (1994) Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 50: 272-298.
21. Capewell S, O'Flaherty M (2008) Maximising secondary prevention therapies in patients with coronary heart disease. Heart 94: 8-9.
22. Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
23. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 71: 117-125.
24. Law MR, Wald NJ, Rudnicka A (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423-1427.
25. Lee ET (1992) Statistical Methods for Survival Data Analysis, Second Edition. New York: Wiley.
26. Cox DR (1972) Regression methods of life tables (with discussion). J R Stat Soc B 34: 187-220.
27. Therneau TM, Grambsch PM (2000) Modelling survival data: extending the Cox model. New York: Springer.
28. Newcombe RG (1988) Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur. Stat Med 7: 1179-1186.
29. Glasziou PP (1992) Meta-analysis adjusting for non-compliance: the example of breast cancer screening. J Clin Epidemiol 45: 1251-1256.
30. Frangakis CE, Rubin DB (1999) Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes. Biometrika 86: 365-379.
31. Robins JM, Greenland S (1994) Adjusting for differential rates of prophylaxis therapy for PCP in high- versus low-dose AZT treatment arms in an AIDS randomized trial. J Am Stat Assoc 89: 737-749.
32. Cuzick JK, Edwards R, Segnan N (1997) Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 16: 1017-1029.
33. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
34. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, et al. (2004) The Study on Cognition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 22: 1605-1612.
35. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, et al. (2007) Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369: 1431-149.
36. ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840.
37. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502.
38. ACCORD Study Group (2007) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99(S): 21i-33i.